EUVIMEDEUVIMED entdecken
Crossref

Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation

Hefeng Geng, Fangyuan Zheng, Wentao Sun, Shuoqi Huang, Zhiya Wang, Kaisi Yang, Chengkang Wang, Caizhi Tian, Chang Xu, Guanchao Zhai, Mingyi Zhao, Shanbo Hou und 3 weitere

International Immunopharmacology · 2024-12 · 143 · 113333

DOI: 10.1016/j.intimp.2024.113333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024-12. Verfasst von Hefeng Geng und 14 weiteren Autor:innen. Beteiligte Einrichtung: Teaching Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command, 100016 Shenyang City, Liaoning Province, PR Ch…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Apoptosis, Histone Deacetylase Inhibitors, Cell Proliferation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Histone deacetylase (HDAC) is a potential target for Colorectal Cancer (CRC) molecular target therapy, dehydroharmine derivative ZDLT-1 was designed to inhibit CRC cell proliferation by inhibiting HDAC target. This study aimed to explore the effect of ZDLT-1 could induce apoptosis in CRC in vitro and in vivo, and determine the mechanism of ZDLT-1. METHODS: First, MTT assay, colony formation, wound healing, Transwell assay, Hoechst33342 staining and Annexin V-FITC/PI double staining assay were used to investigate the in vitro effect of ZDLT-1. Second, the toxicity and the anti-tumor effect of ZDLT-1 by subcutaneous tumorigenesis assay were used to determine the in vivo effect of ZDLT-1. In terms of mechanism, we evaluated the effect of ZDLT-1 on HDAC downstream proteins such as HIF-1α, NF-κB, Cleaved-Caspase-3/9, GSDMD and acetylated histone by immunofluorescence and Western blot assessments. RESULTS: This study confirmed that ZDLT-1 had anti-tumor activity by inhibiting cell proliferation in vitro and solid tumor growth in vivo. Furthermore, ZDLT-1 can inhibit CRC cell invasion, migration and apoptosis in vitro. Moreover, ZDLT-1 can promote the expression of apoptosis proteins in HIF-1α/Caspase-3/Caspase-9 pathway and inhibit the expression of tumor-related immune proteins mainly in NF-κB/GSDMD/GSDME pathway. CONCLUSION: ZDLT-1 as HDAC inhibitor could suppresses CRC cell growth in vivo and in vitro by triggering HIF-1α/Caspase-3/Caspase-9 pathway in promoting apoptosis, and triggering NF-κB/GSDMD/GSDME pathway in inhibiting tumor inflammation. Our results propose dehydroharmine derivative ZDLT-1 as a promising therapeutic small molecular agent for CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsApoptosisHistone Deacetylase InhibitorsCell ProliferationHumansAnimalsXenograft Model Antitumor AssaysMice, NudeMiceCell Line, TumorMice, Inbred BALB CNF-kappa BAntineoplastic AgentsHistone DeacetylasesInflammationMaleCell MovementHypoxia-Inducible Factor 1, alpha SubunitHCT116 Cells

Stichwörter der Autor:innen

ApoptosisColorectal cancerDehydroharmine derivative ZDLT-1HDAC inhibitorInflammation

Substanzen

Histone Deacetylase InhibitorsNF-kappa BAntineoplastic AgentsHistone DeacetylasesHypoxia-Inducible Factor 1, alpha Subunit

Autor:innen und Institutionen

  • Teaching Hospital of Shenyang Pharmaceutical University, General Hospital of Northern Theater Command, 100016 Shenyang City, Liaoning Province, PR China; Department of Clinical Pharmacy, Shenyang Pharmaceutical Universi…
  • Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang City, Liaoning Province, PR China. Electronic address: s17824267658@163.com.
  • Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang City, Liaoning Province, PR China; Pharmacy Department, Tianjin Hospital, Tianjin, PR China. Electronic address: hsq199696@163.com.
  • Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang City, Liaoning Province, PR China. Electronic address: syphu_tiancaizhi@163.com.
  • Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang City, Liaoning Province, PR China. Electronic address: z1098319369@163.com.
  • Department of Clinical Pharmacy, Shenyang Pharmaceutical University, Shenyang City, Liaoning Province, PR China. Electronic address: zmy_dl@126.com.

Zitieren

APA

Geng, H., Zheng, F., Sun, W., Huang, S., Wang, Z., Yang, K., Wang, C., Tian, C., Xu, C., Zhai, G., Zhao, M., Hou, S., Song, A., Zhang, Y., & Zhao, Q. (2024). Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation. International Immunopharmacology, 143, 113333. https://doi.org/10.1016/j.intimp.2024.113333

Vancouver

Geng H, Zheng F, Sun W, Huang S, Wang Z, Yang K, et al. Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation. International Immunopharmacology. 2024;143:113333. doi:10.1016/j.intimp.2024.113333

BibTeX
@article{Geng2024,
  author = {Geng, Hefeng and Zheng, Fangyuan and Sun, Wentao and Huang, Shuoqi and Wang, Zhiya and Yang, Kaisi and Wang, Chengkang and Tian, Caizhi and Xu, Chang and Zhai, Guanchao and Zhao, Mingyi and Hou, Shanbo and Song, Aigang and Zhang, Yingshi and Zhao, Qingchun},
  title = {Effect and mechanism of novel HDAC inhibitor ZDLT-1 in colorectal cancer by regulating apoptosis and inflammation},
  journal = {International Immunopharmacology},
  year = {2024},
  volume = {143},
  pages = {113333},
  doi = {10.1016/j.intimp.2024.113333}
}
Kostenlos starten →